Zonisamide: chemistry, mechanism of action, and pharmacokinetics

  title={Zonisamide: chemistry, mechanism of action, and pharmacokinetics},
  author={Ilo E. Leppik},
  • I. Leppik
  • Published 1 December 2004
  • Biology
  • Seizure

Figures and Tables from this paper

Zonisamide-induced acute kidney injury
Zonisamide – An Overview
US clinical trials show that zonisamide is a safe and effective AED for the treatment of refractory partial-onset seizures, and results from placebo-controlled, short-term studies, as well as baseline or historicalcontrolled, long- term studies, demonstrate thatZonisamide was well-tolerated; most adverse events were mild to moderate, and their incidence declined as treatment continued.
Suivi thérapeutique pharmacologique du zonisamide.
Zonisamide is a second generation antiepileptic drug that provides a mechanism of action similar to those of phenytoin or carbamazepine and is indicated in association in the treatment of partial epilepsy with or without secondary generalization.
Evaluation of zonisamide for the treatment of focal epilepsy: a review of pharmacokinetics, clinical efficacy and adverse effects
  • S. Janković
  • Medicine
    Expert opinion on drug metabolism & toxicology
  • 2020
Zonisamide is an anticonvulsant with multiple mechanisms of action on neuronal tissue, which achieves seizure freedom in more than 80% of patients with newly-onset focal epilepsy and in 6.2 to 18.1% of Patients with focal onset seizures inadequately controlled by first-line anticonVulsants.
Zonisamide for the treatment of Parkinson’s disease
  • H. Miwa
  • Medicine, Psychology
    Expert review of neurotherapeutics
  • 2007
It is expected that zonisamide will be safe and tolerated in patients with PD, as it has been used as an antiepileptic for more than 15 years; however, further studies are required to evaluate its safety and tolerability in the treatment of PD.
Activation by Zonisamide, a Newer Antiepileptic Drug, of Large-Conductance Calcium-Activated Potassium Channel in Differentiated Hippocampal Neuron-Derived H19-7 Cells
This study suggests that, in hippocampal neurons during the exposure to ZNS, the ZNS-mediated effects on BKCa channels and A-type K+ current could be potential mechanisms through which it affects neuronal excitability.
Discovery of Benzenesulfonamide Derivatives as Carbonic Anhydrase Inhibitors with Effective Anticonvulsant Action: Design, Synthesis, and Pharmacological Evaluation.
Two series of novel benzenesulfonamide derivatives were synthesized and evaluated for their human carbonic anhydrase inhibitory activity, and these sulfonamides effectively abolished induced seizures in both models.


Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative.
Metabolism of zonisamide in vitro by hepatic subcellular fractions and cultured gastrointestinal flora produced a single metabolite, 2-(sulphamoylacetyl)-phenol (2-SMAP), by reductive cleavage of the 1,2-benzisoxazole ring.
Steady‐State Pharmacokinetics of Zonisamide, an Antiepileptic Agent for Treatment of Refractory Complex Partial Seizures
A 56‐day pharmacokinetic study of zonisamide was conducted in 24 healthy volunteers, and steady state was achieved in 29 days including two dose escalations, and in an average of 15 days from the last dose adjustment, demonstrating that zonisamia is not an autoinducer.
Formation of 2-sulphamoylacetylphenol from zonisamide under aerobic conditions in rat liver microsomes.
The results imply that zonisamide is metabolized reductively to SMAP by a cytochrome P450 belonging to the 3A subfamily under aerobic conditions as well as anaerobic conditions.
The necessity of adjusting the dosage of zonisamide when coadministered with other anti-epileptic drugs.
Findings show that when ZNS is administered concomitantly with these anti-epileptic drugs, it is necessary to monitor the plasma concentration of ZNS in order to adjust its dosage.
Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative
The metabolism of zonisamide in vitro was characterized through aerobic and anaerobic incubations with rat liver subcellular fractions and cultured gastrointestinal microflora and produced a single metabolite, 2-(sulphamoylacetyl)-phenol (2-SMAP), by reductive cleavage of the 1,2-benzisoxazole ring.